Biotech

All Articles

Analysts examine Avidity's DMD win, uncovering nuances in information

.Avidity Biosciences amazed clients with stage 1/2 information in Duchenne muscular dystrophy (DMD) ...

Actinogen's cortisol blocker neglects period 2 depression research study

.Actinogen Medical's cortisol blocker has actually skipped the main endpoint of a stage 2 research i...

Bivictrix chooses going private only means to take ADC right into center

.Antibody-drug conjugates (ADCs) have been at the facility of numerous a billion-dollar biobuck lice...

TPG leadings up funds to $580M for financial investments across life scientific researches

.Possession supervisor TPG, which has actually sustained biotechs such as Sionna Therapies as well a...

Merck quits phase 3 TIGIT test in bronchi cancer cells for impossibility

.Merck &amp Co.'s TIGIT course has endured yet another drawback. Months after shuttering a stage 3 m...

After a difficult year, Exscientia folds up right into Recursion

.After a year defined by pipe hairstyles, the shift of its own CEO and also cutbacks, Exscientia wil...

Cullinan, after $25M deal, return bispecific to Harbour

.Cullinan Therapy was actually thrilled good enough with Harbour BioMed's bispecific immune system a...

A better check out Brutal Biotech's Ferocious 15

.In this particular full week's incident of "The Leading Pipe," our company are actually diving in t...

Lilly encounters stage 2 breakdown of tau-targeting med

.The confetti is actually still flying coming from Eli Lilly's celebration commemorating the approva...

Biogen CMO Maha Radhakrishnan signs up with Sofinnova-- Chutes &amp Ladders

.Invite to this week's Chutes &amp Ladders, our roundup of substantial management hirings, firings a...